Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about the work.

Table of contents:

Content	Page
Supplementary table 1 (S1)	1

Supplementary Table S1: Baseline demographic and laboratory characteristics of semaglutide case series and participants from the control arms of 4 different studies in new onset T1DM (2-5). Data is presented as mean±SD or percentages (%) when appropriate. – indicates missing data

	Semaglutide case series	Adult historical control (IL-21 Ab study)[2]	Adult historical control (tocilizumab study)[3]	Adult historical control (Imitinab study)[4]	Pediatric and adolescent historical control (4T study)[5]
N	10	77	20	22	46
Gender, F (%)	5 (50)	28 (36)	7(35)	12 (55)	21 (45)
Age (years)	27.0±6.3	29.0±7.0	29.2±9.3	29.0±7.0	9.7±2.3
White Race (%)	90	-	95	95	41
BMI (kg/m²)	25.1±1.6	24.0±5.0	25.4±3.5	22.5±2.2	22.3±2.2
Weight (Kg)	78.4±8.3	72.8±19.8	77.8±14.9	65.8±5.7	91.0±6.0
HbA1c (%)	11.7±2.1	7.3±1.3	7.2±1.2	7.1±1.2	11.9±2.1
Days since diagnosis	33±19	71±33	85±12	84±11	At diagnosis
Fasting C-peptide (ng/mL)	0.65±0.33	0.69±0.45	-	0.94±0.21	-
T1DM autoantibodies(name or number) (%)	GAD Ab (90) IA2 Ab (50) IC Ab (20)	1 (36) 2 (31) 3 (32)	100% with 1 or more Ab	GAD Ab (91) IA2 Ab (64) IC Ab (68)	-
Basal Insulin dose (U/kg)	0.21±0.12	0.19±0.11	-	0.17±0.09	-
Bolus insulin dose (U/kg)	0.15±0.09	0.16±0.12	-	0.11±0.07	-
Total Insulin dose (U/kg)	0.35±0.11	0.32±0.21	0.30±0.21	0.28±0.09	-